Particularly, we reported new subtypes of tumor-associated CD8+ T cells characterized by different TBX21 and BHLHE40 activity, both of which are known regulators of CD8+ T cell functionality (Lutter et al., 2022; Pritchard et al., 2023; Salmon et al., 2022; Trapani, 2001). Here, CD8A is linked to neoplasm.